On March 20, 2025, Opus Genetics, Inc. announced an expected net loss of about $56.8 million and cash used in operations of approximately $25.6 million for the year ended December 31, 2024, with cash and cash equivalents estimated at $30.3 million as of that date, noting these figures are preliminary and subject to change.